A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

brivanib (active)

Tablet, Oral, Brivanib 800 mg, once daily, until progression

Trial Locations (37)

112

Local Institution, Taipei

704

Local Institution, Tainan City

1102

Local Institution, Quezon

6000

Local Institution, Cebu City

8000

Local Institution, Davao City

13273

Local Institution, Marseille

17033

Penn State Milton S. Hershey Medical Center, Hershey

19141

Albert Einstein Cancer Center, Philadelphia

19713

Christiana Care Health Services, Newark

27710

Duke University Medical Center, Durham

33136

University Of Miami Miller School Of Medicine, Miami

35042

Local Institution, Rennes

48201

Wayne State University, Detroit

51092

Local Institution, Reims

52242

University Of Iowa Hospitals And Clinics, Iowa City

53226

Medical College Of Wisconsin, Milwaukee

56000

Local Institution, Kuala Lumpur

60611

Northwestern University Feinberg School Of Medicine, Chicago

60637

University Of Chicago, Chicago

63104

Saint Louis University, St Louis

71800

Local Institution, Kampung Baharu Nilai

75390

Univ Of Texas Southwestern, Dallas

77030

Md Anderson Cancer Center, Houston

90095

Harbor-Ucla Medical Center, Los Angeles

91010

City Of Hope National Medical Center, Duarte

94805

Local Institution, Villejuif

169610

Local Institution, Singapore

308433

Local Institution, Singapore

91010-3000

City Of Hope National Medical Center, Duarte

90095-1678

Harbor UCLA Medical Center, Los Angeles

07601

The Cancer Center At Hackensack University Medical Center, Hackensack

77030-4009

MD Anderson Cancer Center, Houston

Unknown

Local Institution, Shatin, Nt.,

410-769

Local Institution, Gyeonggi-do

135-710

Local Institution, Seoul

138-736

Local Institution, Seoul

152-703

Local Institution, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY